Amit Gruber

Amit Gruber

Auto-generated profile, based on publicly available information

Amit Gruber

The Heart Failure Unit, Department of Cardiology, Rambam Health Care Campus, Haifa 3109601, Israel

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
OAOmer Adir
Omer Adir
MAMia R. Albalak
Mia R. Albalak
RARavit Abel
Ravit Abel
LWLucien E. Weiss
Lucien E. Weiss
GCGal Chen
Gal Chen
ASAvi Schroeder
Avi Schroeder
Development of regulated cellular processes and signaling methods in synthetic cells is essential for their integration with living materials. Light is an attractive tool to achieve this, but the limited penetration depth into tissue of visible light restricts its usability for in-vivo applications. Here, we describe the design and implementation of bioluminescent intercellular and intracellular signaling mechanisms in synthetic cells, dismissing the need for an external light source. First, we engineer light generating SCs with an optimized lipid membrane and internal composition, to maximize luciferase expression levels and enable high-intensity emission. Next, we show these cells’ capacity to trigger bioprocesses in natural cells by initiating asexual sporulation of dark-grown mycelial cells of the fungus Trichoderma atroviride. Finally, we demonstrate regulated transcription and membrane recruitment in synthetic cells using bioluminescent intracellular signaling with self-activating fusion proteins. These functionalities pave the way for deploying synthetic cells as embeddable microscale light sources that are capable of controlling engineered processes inside tissues.

8 June 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
AGAmit Gruber
Amit Gruber
OEOded Edri
Oded Edri
IHIrit Huber
Irit Huber
GAGil Arbel
Gil Arbel
AGAmira Gepstein
Amira Gepstein
LGLior Gepstein
Lior Gepstein
Abnormal action potential (AP) properties, as occurs in long or short QT syndromes (LQTS and SQTS, respectively), can cause life-threatening arrhythmias. Optogenetics strategies, utilizing light-sensitive proteins, have emerged as experimental platforms for cardiac pacing, resynchronization, and defibrillation. We tested the hypothesis that similar optogenetic tools can modulate the cardiomyocyte’s AP properties, as a potentially novel antiarrhythmic strategy. Healthy control and LQTS/SQTS patient–specific human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) were transduced to express the light-sensitive cationic channel channelrhodopsin-2 (ChR2) or the anionic-selective opsin, ACR2. Detailed patch-clamp, confocal-microscopy, and optical mapping studies evaluated the ability of spatiotemporally defined optogenetic protocols to modulate AP properties and prevent arrhythmogenesis in the hiPSC-CMs cell/tissue models. Depending on illumination timing, light-induced ChR2 activation induced robust prolongation or mild shortening of AP duration (APD), while ACR2 activation allowed effective APD shortening. Fine-tuning these approaches allowed for the normalization of pathological AP properties and suppression of arrhythmogenicity in the LQTS/SQTS hiPSC-CM cellular models. We next established a SQTS–hiPSC-CMs–based tissue model of reentrant-arrhythmias using optogenetic cross-field stimulation. An APD-modulating optogenetic protocol was then designed to dynamically prolong APD of the propagating wavefront, completely preventing arrhythmogenesis in this model. This work highlights the potential of optogenetics in studying repolarization abnormalities and in developing novel antiarrhythmic therapies.

1 March 2025 in Circulation: Heart Failure
Verified
Journal Article
Closed access
IHIdan Refael Haim
Idan Refael Haim
AGAmit Gruber
Amit Gruber
NKNoam Kazma
Noam Kazma
CBCaroline Bashai
Caroline Bashai
HKHava Lichtig Kinsbruner
Hava Lichtig Kinsbruner
OCOren Caspi
Oren Caspi
BACKGROUND: The therapeutic armamentarium for heart failure with preserved ejection fraction (HFpEF) remains notably constrained. A factor contributing to this problem could be the scarcity of in vitro models for HFpEF, which hinders progress in developing new therapeutic strategies. Here, we aimed at developing a novel, comorbidity-inspired, human, in vitro model for HFpEF. METHODS: Human induced pluripotent stem cells–derived cardiomyocytes were used to produce cardiac organoids. The generated organoids were then subjected to HFpEF-associated, comorbidity-inspired conditions, such as hypertension, diabetes, and obesity-related inflammation. To assess the development of HFpEF pathophysiological features, organoids were thoroughly evaluated for their structural, functional, electrophysiological, and metabolic properties. RESULTS: Exposure to the combination of all comorbidity-mimicking conditions resulted in the largest cellular volume of 1692±52 versus 1346±84 µm 3 in RPMI (Roswell Park Memorial Institute medium) control group ( P =0.003), while lower in obesity, hypertension, and diabetes groups: 1059±40 µm 3 ( P =0.014), 1276±35 µm 3 ( P =0.940), and 1575±70 µm 3 ( P =0.146), respectively. Similarly, ultrastructural fibrosis was most significantly observed after exposure to the combination of all HFpEF-inducing conditions 14.6±1.2% compared with single condition exposure 5.2±1.3% (obesity), 6.7±3.5% (hypertension), and 9.0±1.1% (diabetes; P <0.001). Moreover, HFpEF-related conditions led to an increase in passive force compared with control (7.52±1.08 versus 2.33±0.46 mN/mm, P <0.001), whereas no significant alterations were noted in active contractile forces. Relaxation constant τ was significantly prolonged after exposure to HFpEF conditions showing a prolongation of 95.9 ms (36.4–106.4; P =0.028) compared with a shortening of 35.6 ms (43.3–67.3; P =0.80) in the control. Finally, organoid exposure to HFpEF conditions led to a significant increase in oxidative stress levels and a significant decline in oxygen consumption rate. CONCLUSIONS: We established a novel, human, in vitro model for HFpEF, based on comorbidity-inspired conditions. The model faithfully recapitulated the structural, functional, and mechanistic features of HFpEF. This model holds the potential to provide mechanistic insights and facilitate the identification of novel therapeutic targets.

15 February 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
AGAmit Gruber
Amit Gruber
OEOded Edri
Oded Edri
SGShany Glatstein
Shany Glatstein
IGIdit Goldfracht
Idit Goldfracht
IHIrit Huber
Irit Huber
LGLior Gepstein
Lior Gepstein
Background: Optogenetics, using light‐sensitive proteins, emerged as a unique experimental paradigm to modulate cardiac excitability. We aimed to develop high‐resolution optogenetic approaches to modulate electrical activity in 2‐ and 3‐dimensional cardiac tissue models derived from human induced pluripotent stem cell (hiPSC)‐derived cardiomyocytes. Methods and Results: To establish light‐controllable cardiac tissue models, opsin‐carrying HEK293 cells, expressing the light‐sensitive cationic‐channel CoChR, were mixed with hiPSC‐cardiomyocytes to generate 2‐dimensional hiPSC‐derived cardiac cell‐sheets or 3‐dimensional engineered heart tissues. Complex illumination patterns were designed with a high‐resolution digital micro‐mirror device. Optical mapping and force measurements were used to evaluate the tissues' electromechanical properties. The ability to optogenetically pace and shape the tissue's conduction properties was demonstrated by using single or multiple illumination stimulation sites, complex illumination patterns, or diffuse illumination. This allowed to establish in vitro models for optogenetic‐based cardiac resynchronization therapy, where the electrical activation could be synchronized (hiPSC‐derived cardiac cell‐sheets and engineered heart tissue models) and contractile properties improved (engineered heart tissues). Next, reentrant activity (rotors) was induced in the hiPSC‐derived cardiac cell‐sheets and engineered heart tissue models through optogenetics programmed‐ or cross‐field stimulations. Diffuse illumination protocols were then used to terminate arrhythmias, demonstrating the potential to study optogenetics cardioversion mechanisms and to identify optimal illumination parameters for arrhythmia termination. Conclusions: By combining optogenetics and hiPSC technologies, light‐controllable human cardiac tissue models could be established, in which tissue excitability can be modulated in a functional, reversible, and localized manner. This approach may bring a unique value for physiological/pathophysiological studies, for disease modeling, and for developing optogenetic‐based cardiac pacing, resynchronization, and defibrillation approaches.

8 May 2026 in Circulation Research
Verified
Journal Article
Closed access
MGMatteo Ghiringhelli
Matteo Ghiringhelli
DSDaniel Shiff
Daniel Shiff
HGHarel Grinstein
Harel Grinstein
TKTahel Kerem
Tahel Kerem
AGAmit Gruber
Amit Gruber
LGLior Gepstein
Lior Gepstein
BACKGROUND: The study of atrial arrhythmias has been hampered by the lack of anatomically relevant human cardiac tissue models and by the inability to perform targeted, functional perturbations in such models. METHODS: To engineer anatomically relevant light-sensitive atrial chambers, we combined human pluripotent stem cells, differentiation protocols yielding atrial and sinoatrial nodal cells, rat heart decellularization/recellularization processes, and optogenetics tools. RESULTS: Immunostaining for chamber-specific cardiomyocyte markers, optical action potential recordings, and the response to atrial-specific pharmacology confirmed the atrial-specific identity of the recellularized engineered tissue. Histological examination verified the preservation of the macroscopic and microscopic atrial architecture of the engineered atria. Optical mapping showed the ability of seeded human pluripotent stem cell–derived sinoatrial nodal cells at the correct anatomic site to serve as a biological pacemaker. Adenoviral transduction and transgenic human pluripotent stem cells were used to express the light-sensitive channels, ChR2 (channelrhodopsin-2) or CoChR ( chloromonas oogama channelrhodopsin), in the bioengineered atria, allowing optogenetic pacing and programmed stimulation. Reentrant arrhythmias could be induced and optically mapped in the bioengineered atrial tissue models, demonstrating the ability to recapitulate and provide insights into different atrial fibrillation mechanisms. These arrhythmias could be terminated by localized (focal or linear) or diffused optogenetic silencing (optogenetic cardioversion). CONCLUSIONS: A novel, light-controllable, bioengineered humanized biatrial tissue model was established and could be used to model different atrial arrhythmias, for drug testing, for disease modeling, and for evaluation of novel therapeutic interventions such as biological pacemaking and optogenetic interventions.

18 May 2026 in European Heart Journal - Cardiovascular Pharmacotherapy
Verified
Journal Article
Open access
IVIna Volis
Ina Volis
AGAmit Gruber
Amit Gruber
AAAharon (Ronnie) Abbo
Aharon (Ronnie) Abbo
DADoron Aronson
Doron Aronson
NGNicolas Girerd
Nicolas Girerd
OCOren Caspi
Oren Caspi
In chronic heart failure (HF), decongestion is hindered by reduced renal function and diuretic resistance. This study compared the effect of eGFR and serum bicarbonate on three diuretic regimens in congestion-refractory HF patients. This is a prespecified post-hoc analysis of DEA-HF, a randomized, crossover trial (n = 42). Patients received, in random order, weekly treatments of IV furosemide 250 mg; oral metolazone 5mg + IV furosemide 250 mg; and IV acetazolamide 500mg + IV furosemide 250 mg. Primary endpoint: 6h-Natriuresis; secondary: 6h-diuresis and decongestion measures at 7 ± 3 days. Mixed models assessed effect modification by eGFR (≤30 vs. > 30 mL/min/1.73m2) and by serum bicarbonate (≤vs.> median-29.6 mmol/L). Higher eGFR was associated with greater natriuresis and diuresis (4735 mg vs. 3211 mg, P = 0.0004; 1.93L vs. 1.49L, P = 0.0078). In patients with eGFR > 30, addition of metolazone to furosemide led to higher natriuresis compared to acetazolamide addition (5525 mg vs. 4379 mg, P = 0.04) or to furosemide monotherapy (5525 mg vs. 4303 mg, P = 0.014); no regimen differences were observed at eGFR ≤ 30. Independently, higher serum bicarbonate predicted greater natriuresis and diuresis (4858 mg vs. 3576 mg, P = 0.0008; 1.99 vs. 1.56L, P = 0.0014). There was no difference in clinical decongestion measures. All regimens were well-tolerated with comparable safety concerns regarding renal function, electrolyte disturbances, or hypotension. In ambulatory patients with congestion-refractory HF and eGFR > 30 mL/min/1.73m2, natriuretic and diuretic responses are augmented across all regimens, with metolazone providing additional improvement in natriuresis. When eGFR ≤ 30 mL/min/1.73m2, neither metolazone nor acetazolamide provides additional benefit. High serum bicarbonate predicts better natriuretic and diuretic response, as well as additional benefit from metolazone treatment. High-dose diuretics had comparable safety profiles across the eGFR spectrum.